Enlivex Therapeutics (Enlivex Therapeutics) Change In Payables And Accrued Expense : $-1.47 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Change In Payables And Accrued Expense?

Enlivex Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2023 was $-0.69 Mil. It means Enlivex Therapeutics's Accounts Payable & Accrued Expense declined by $0.69 Mil from Jun. 2023 to Sep. 2023 .

Enlivex Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was $1.85 Mil. It means Enlivex Therapeutics's Accounts Payable & Accrued Expense increased by $1.85 Mil from Dec. 2021 to Dec. 2022 .

Enlivex Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Enlivex Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Change In Payables And Accrued Expense Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.89

-1.99

-0.02

1.85

-1.47

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															2.07	-1.18	-0.45	-0.69	0.85

Enlivex Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47 Mil.

Enlivex Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ENLV:Israel 1BT:Germany

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.